10-Q: China Pharma Holdings Faces Going Concern Amid Revenue Decline

China Pharma Holdings reports continued net losses and declining revenue, raising substantial doubt about its ability to continue as a going concern.

Summary

• China Pharma Holdings, Inc. (CPHI) reported a net loss of $1.97 million for the nine months ended September 30, 2025, an improvement from a $3.51 million net loss in the same period of 2024.
• Revenue decreased by 14% to $2.92 million for the nine months ended September 30, 2025, compared to $3.39 million in the prior year.
• The company's current liabilities exceeded current assets by $4.3 million as of September 30, 2025, and cash and cash equivalents stood at $0.27 million.
• Management has identified substantial doubt about the company's ability to continue as a going concern within one year.
• A significant write-off of $13.7 million in accounts receivable aged over eight years occurred in August 2025.
• The company acquired a new patent, 'Apremilast Vector and method for its preparation,' for $2.45 million, paid through the issuance of 1,760,000 common shares.
• Disclosure controls and procedures were deemed ineffective due to a material weakness related to a lack of U.S. GAAP-knowledgeable accounting personnel.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the explicit 'going concern' warning, continued revenue decline in core pharmaceutical products, significant working capital deficit, and identified material weakness in internal controls. While net loss improved and cash used in operations decreased, these are overshadowed by fundamental solvency and operational challenges.

Positives

• Net loss significantly improved to $1.97 million for the nine months ended September 30, 2025, from $3.51 million in the prior year.
• Gross loss improved to $0.28 million (9.7% gross loss margin) for the nine months ended September 30, 2025, from $1.83 million (53.8% gross loss margin) in the prior year, primarily due to lower depreciation and a reduction in inventory obsolescence.
• Cash used in operating activities decreased substantially to $3,729 for the nine months ended September 30, 2025, from $704,836 in the same period of 2024.
• The company acquired a new patent for Apremilast Vector, expanding its intangible assets by $2.45 million.

Negatives

• Revenue declined by 14% to $2.92 million for the nine months ended September 30, 2025, from $3.39 million in the prior year, mainly due to increased competition from Centralized Procurement (CP) and the company's products not passing consistency evaluations.
• The company has an accumulated deficit of $46.0 million as of September 30, 2025, an increase from $44.0 million at December 31, 2024.
• Current liabilities exceeded current assets by $4.3 million as of September 30, 2025, indicating a severe working capital deficit.
• Cash and cash equivalents decreased to $0.27 million as of September 30, 2025, from $0.63 million at December 31, 2024.
• General and administrative expenses increased to $1.37 million for the nine months ended September 30, 2025, from $0.93 million in the prior year, mainly due to increased amortization of intangible assets.
• Credit losses increased to $26,011 for the nine months ended September 30, 2025, from $4,754 in the prior year, despite a large write-off of old receivables.
• The provision for inventory obsolescence increased to $1.09 million as of September 30, 2025, from $0.57 million at December 31, 2024.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to continued operating losses, debt service costs, and selling and administrative costs.
• Reliance on the Chairperson, CEO, and Interim CFO, Ms. Li, for working capital advances, totaling $1.41 million as of September 30, 2025, with no assurance of future advances.
• Exposure to political, economic, and legal environments in the PRC, including fluctuations in foreign currency exchange rates and governmental policies on anti-inflationary measures, currency conversion, and taxation.
• Impact of China's Centralized Procurement (CP) activities, which significantly reduce drug prices and require consistency evaluation, making market access challenging for products that have not passed evaluation.
• Concentration risk with two customers accounting for 45.0% and 15.0% of accounts receivable, and three suppliers for 25.7%, 21.1%, and 12.2% of raw material purchases for the nine months ended September 30, 2025.
• Concentration risk with three products accounting for 30.9%, 24.4%, and 11.2% of revenue for the nine months ended September 30, 2025.
• Restrictions on dividend distribution and remittance of funds out of the PRC due to statutory surplus reserve requirements and currency exchange controls.

Future Outlook

Management anticipates continued operating losses for the foreseeable future. The company plans to enhance its advance payment sales model, strengthen accounts receivable collection, explore strategic alternatives for nutrition products, and use existing property as collateral for additional bank loans. Cost reduction measures across procurement, production, human resources, and marketing are also planned. However, these plans are not considered probable of effective implementation or mitigation of the going concern risk at this time.

Management Comments

• Management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable.
• The Company is currently exploring strategic alternatives to accelerate the launch of nutrition products.
• Management believes that the Companys existing property, plant and equipment can serve as collateral to support additional bank loans.
• The Company will implement multiple measures simultaneously across procurement, production, human resources, and marketing to reduce operating costs.
• Helpson has always taken the task of promoting the consistency evaluation as a top priority, and worked on them actively. However, for each drugs consistency evaluation, due to the continuous dynamic changes of the detailed consistency evaluation policies, market trends, expected investments, and expected returns of investment (ROI), the whole industry, including Helpson, has been making slow progresses in terms of the consistency evaluation.
• Our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2025 to satisfy the objectives for which they are intended. This was due to the material weakness in our internal control over financial reporting, with respect to our lack of accounting financial reporting personnel who were knowledgeable in U.S. GAAP.

Industry Context

The Chinese pharmaceutical market is heavily influenced by government-led Centralized Procurement (CP) activities, which have significantly reduced drug prices and require consistency evaluations for market participation. This policy has negatively impacted companies like China Pharma Holdings whose products have not yet passed these evaluations. The company is also exploring the broader 'comprehensive healthcare' sector, including nutrition products, sanitizers, and masks, in response to evolving social needs and government initiatives like 'Healthy China 2030'.

Corporate Governance

Related Party Transactions

• The company owed its Chairperson, Ms. Li, $1,413,340 as of September 30, 2025, for working capital advances, including an additional $0.27 million advanced during fiscal 2025.
• A loan agreement with Chairperson Li for RMB 4,770,000 ($738,379) bears 4.35% interest and is due July 9, 2026, with annual extensions.
• Compensation payable to Chairperson Li is included in Other payables, totaling $1,611,506 as of September 30, 2025.
• The Chairperson and Chief Executive Officer personally guaranteed a new line of credit facility obtained on June 25, 2025, and pledged personal assets as collateral.
• The Chairperson and Chief Executive Officer personally guaranteed a three-year revolving loan obtained on September 25, 2023.

Stakeholder Impact

• Shareholders face significant risk due to the 'going concern' uncertainty, declining core revenue, and potential for further dilution if equity financing is pursued.
• Creditors, particularly those with unsecured loans or guarantees not personally backed by management, face increased risk given the company's liquidity issues and working capital deficit.
• Employees may face uncertainty regarding job security and operational stability given the company's cost reduction initiatives and overall financial distress.
• Customers may experience potential disruptions in product availability or service if the company's financial condition deteriorates further, though the company aims to enhance sales models and product offerings.
• Suppliers may face delayed payments or renegotiated terms due to the company's liquidity challenges and efforts to consolidate purchasing activities to enhance bargaining power.

Next Steps

• Management plans to enhance the sales model of advance payment and strengthen accounts receivable collection.
• The company is exploring strategic alternatives to accelerate the launch of nutrition products.
• Management intends to use existing property, plant, and equipment as collateral to support additional bank loans.
• Implementation of multiple measures across procurement, production, human resources, and marketing to reduce operating costs.
• Continued efforts in consistency evaluations for existing pharmaceutical products, albeit with a cautious and flexible approach.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt about its ability to continue as a going concern.' Core pharmaceutical revenue is declining due to competitive pressures from government policies (Centralized Procurement), and there's a significant working capital deficit. While net loss improved, this is largely due to non-operational factors like depreciation and a large write-off of old receivables, not a fundamental turnaround. The reliance on related-party loans and the identified material weakness in internal controls further compound the risks. Given these fundamental solvency issues and operational challenges, a strong sell recommendation is warranted for any investor.

Keywords

Pharmaceuticals, China, SEC Filing, 10-Q, Going Concern, Revenue Decline, Net Loss, Centralized Procurement, Drug Consistency Evaluation, Hainan Helpson, CPHI, Financial Reporting, Internal Controls